Lonafarnib for cancer and progeria.

摘要: Introduction: Lonafarnib is a non-peptidomimetic inhibitor of farnesyl transferase, an enzyme responsible for the post-translational lipid modification wide variety cellular proteins that are involved in pathogenic pathways various diseases including cancer and progeria. Although extensive clinical research indicates limited activity lonafarnib solid tumors, there recent interest combinations transferase inhibitors with imatinib or bortezomib hematological malignancies to investigate role Areas covered: This review examines vitro vivo pharmacology available data monotherapy combination therapy treatment as well progeria, using studies identified from PubMed database supplemented by computerized search relevant abstracts major hematology conferences. Expert opinion: There no evidence suppor...